[Transthyretin familial amyloid polyneuropathy]

Area of Science:

• Neurology
• Genetics
• Cardiology

Background:

• Transthyretin family amyloid polyneuropathy (TTR-FAP) is a progressive, fatal disease.
• Caused by extracellular deposition of transthyretin amyloid fibrils.
• Over 100 mutations in the transthyretin gene are known.

Purpose of the Study:

• To address the pathogenesis, diagnosis, and treatment of TTR-FAP.
• Highlight the challenges in diagnosing TTR-FAP due to phenotypic diversity.
• Emphasize the risks associated with misdiagnosis.

Main Methods:

• Review of existing literature on TTR-FAP pathogenesis.
• Analysis of diagnostic criteria and challenges.
• Examination of current and emerging treatment strategies.

Main Results:

• TTR-FAP presents with diverse neurological and cardiac symptoms.
• Phenotypic variability complicates clinical diagnosis.
• Delayed or incorrect diagnosis can lead to irreversible organ damage.

Conclusions:

• Accurate and timely diagnosis of TTR-FAP is critical.
• Understanding TTR-FAP pathogenesis is key to developing effective treatments.
• Multidisciplinary approaches are needed for optimal patient management.